Tribunal allows Di-Gesic and Doloxene prescribing to continue

The Administrative Appeals Tribunal (AAT) decided that both Di-Gesic (dextropropoxyphene HCl 32.5mg/paracetamol 325mg) and Doloxene (dextropropoxyphene napsylate) should remain on the Australian Register of Therapeutic Goods (ARTG), subject to the implementation of conditions to promote the safe use of these medicines.

A statement by manufacturers, Aspen Pharmacare, said that the AAT’s decision was made after considering the evidence of scientific and medical experts put forward by both the TGA and Aspen over the course of a week during 2012,